PCYNOTCPharmaceutical PreparationsFiscal year ends June 30
PROCYON CORP
Financials through Q4 FY2024, quarter ended Jun 30, 2024Last filing: 10-K on Oct 25, 2024
$0.18−0.09 (-31.48%)
Close on Oct 19, 2026
- Market cap
- $1.51M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2010 to 2024
Gross margin
78.1%+5.3 pts over 5 years
Operating margin
-4.6%−7.0 pts over 5 years
Net margin
-6.8%−7.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2024
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +6.4% | +1.8% | +3.5% | +5.8% | |
| Gross profit | +9.0% | +4.7% | +5.0% | +6.2% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2015 | FY2019 | FY2024 | Trend |
|---|---|---|---|---|
| Return on equity | – | 1.3% | -13.9% | |
| Return on assets | – | 1.1% | -10.1% | |
| Current ratio | 3.75 | 4.24 | 3.08 | |
| Interest coverage | -1706.8× | – | – | |
| Inventory turnover | 2.3× | 2.5× | 2.3× | |
| Capex to revenue | 2.4% | 0.7% | 1.3% | |
| Diluted shares | 8M | 8M | 8M |
Where the cash went
Fiscal 2020 to 2024, five years combined
Procyon generated $1.07M from operations and spent $414.90K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.07M
Used
$414.90K
Capital expenditure$414.90K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-6.8%
×Asset turnover1.47×
×Equity multiplier1.38×
=Return on equity, FY2024-13.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -6.8% | 1.47× | 1.38× | -13.9% |
| FY2023 | -1.1% | 1.27× | 1.39× | -1.9% |
| FY2022 | -4.3% | 1.20× | 1.46× | -7.6% |
| FY2021 | 14.7% | 1.33× | 1.41× | 27.5% |
| FY2020 | 2.6% | 1.65× | 1.24× | 5.3% |
| FY2019 | 0.6% | 1.75× | 1.17× | 1.3% |
| FY2018 | -6.4% | 1.58× | 1.18× | -11.8% |
| FY2017 | 0.3% | 1.37× | 1.28× | 0.5% |
| FY2016 | 3.2% | 1.22× | 1.27× | 5.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2024 against fiscal 2023
3of 8 tests passed in fiscal 2024. Some tests lack the figures they need.
- ProfitableNet income above zero-$341.14K
- Cash generatingOperating cash flow above zero-$61.25K
- Return on assets improvedROA up on the prior year-1.3% → -9.6%
- Earnings backed by cashOperating cash flow above net income-$61.25K vs -$341.14K
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.57 → 3.08
- No dilutionShare count did not rise8M → 8M
- Gross margin improvedGross margin up on the prior year76.16% → 78.07%
- More efficientAsset turnover rose1.23 → 1.40